Risk factors, co‐morbidities, and co‐medications in cardioprotection: Importance for translation

類似資料

• Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?
  著者:: Kleinbongard, Petra, 等
  出版事項: (2020)
• PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
  著者:: Andreadou, Ioanna, 等
  出版事項: (2020)
• The role of gasotransmitters NO, H(2)S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning
  著者:: Andreadou, Ioanna, 等
  出版事項: (2015)
• Hyperlipidaemia and cardioprotection: Animal models for translational studies
  著者:: Andreadou, Ioanna, 等
  出版事項: (2020)
• Shining the spotlight on cardioprotection: beyond the cardiomyocyte
  著者:: Davidson, Sean M, 等
  出版事項: (2019)